Spitzer W O
Department of Epidemiology and Biostatistics, McGill University, Montreal, Canada.
Br J Clin Pharmacol. 1996 May;41(5):359-63. doi: 10.1046/j.1365-2125.1996.03582.x.
On December 14, 1995, the first public presentation of results of the Transnational Case-Control Study of Oral Contraceptives and the Health of Young Women was made at the winter meeting of the British Pharmacological Society at Brighton. Four weeks later, those results and further analyses were published in the British Medical Journal. There has been much debate about them in Europe and elsewhere. I feel privileged to have been invited to write a Leading Article about the safety of combined oral contraceptives in the British Journal of Clinical Pharmacology. These are personal opinions about the meaning of all the recent pharmacoepidemiological findings. With an historical context as the background I have added my personal reflections as a scientist and a public health doctor. These views do not necessarily reflect the views of my co-investigators.
1995年12月14日,关于口服避孕药与年轻女性健康的跨国病例对照研究结果首次在布莱顿举行的英国药理学会冬季会议上公开汇报。四周后,这些结果及进一步分析发表在《英国医学杂志》上。在欧洲及其他地区,围绕这些结果展开了诸多争论。我很荣幸受邀为《英国临床药理学杂志》撰写一篇关于复方口服避孕药安全性的社论。这些是我对近期所有药物流行病学研究结果意义的个人看法。以历史背景为依托,我融入了作为一名科学家和公共卫生医生的个人思考。这些观点未必反映我的共同研究者们的看法。